Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: TMBPT suppresses colorectal cancer by arresting the cell cycle and triggering apoptosis

PROVIDER: PRJNA884855 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR21733511_1.fastq.gz	Fastqsanger.gz
	SRR21733511_2.fastq.gz	Fastqsanger.gz
	SRR21733512_1.fastq.gz	Fastqsanger.gz
	SRR21733512_2.fastq.gz	Fastqsanger.gz
	SRR21733513_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

Talaroconvolutin-A treated bladder cancer for proteomics sequencing

Project description:TalaA inhibits bladder cancer mainly through two approaches: 1) arresting cell cycle to suppress proliferation, 2) triggering ferroptosis to cause cell death. In molecular mechanism, TalaA can interact with MAPKs to repress the phosphorylation of transcription regulators. This study would open new avenues for bladder cancer treatment targeting MAPKs, inhibiting cell cycle and inducing ferroptosis.

2022-10-27 | PXD037785 |

Novel Eph receptor tyrosine kinase inhibitors block colorectal cancer cell growth

Project description:Despite advances, treatment of unresectable colorectal cancer remains a clinical challenge and the incidence of this malignancy is increasing in individuals below the age of fifty. Integrated genomic, transcriptomic, proteomic, and mechanistic studies identified the tyrosine kinase receptors EphB2 and EphB4 as colorectal cancer drivers, and EphA2 activity as a cancer resistance mechanism to epidermal growth factor receptor and BRAF inhibitors. Reduction of EphB2 and EphB4 activity suppresses colorectal cancer cell growth and survival and is a potential target for colorectal cancer therapy. Here, we report the design and synthesis of two novel inhibitors, 1 and 3, that selectively bind with high affinity to A and B-type Eph receptor tyrosine kinases, inhibit A and B-type Eph tyrosine kinase activity, induce cell cycle arrest and confer a protracted state of growth reduction to colorectal cancer cells. 1 and 3 bind to EphA2 arresting the activation loop containing the conserved Asp-Phe-Gly (“DFG”)-motif in an inactive conformation and show a conserved hydrogen bond interaction with the so-called gatekeeper residue, the activation loop, alphaC helix, and hinge region of the kinase, typical of kinase inhibitors. These results demonstrate that pharmacological inhibition of Eph tyrosine kinase receptors is a valid therapeutic approach for the treatment of colorectal cancer.

2024-05-23 | PXD031880 | Pride

Project description:Repurposing propofol for breast cancer therapy through promoting apoptosis and arresting cell cycle

| PRJNA1103179 | ENA

RNA-Seq analysis of prostate cancer cells after 3-bromopyruvic acid treatment

Project description:We performed RNA-seq analysis using differnt prostate cancer cell lines (PC3 and LNCaP) after 3-bromopyruvic acid treatment. We reported that 3-bromopyruvic acid regulatescell cycle-associated genes in PC3 cells. 3-bromopyruvic acid induces apoptosis and suppresses cell cycle progration, cell migration and invasion in PC3 cells.

2021-07-21 | GSE180328 | GEO

CAPG silencing promotes CRC cell apoptosis and ferroptosis via P53 pathway

Project description:Colorectal cancer (CRC) is the third most common cancer in the world and the second leading cause of cancer-related deaths. However, there are few effective therapeutic targets for colorectal cancer. Here, we report that Capping Actin Protein, Gelsolin Like (CAPG), a protein involved in actin related movement, is significantly overexpressed in human CRC tissues, and that expression levels are inversely correlated with overall survival. CAPG knockdown CRC cell lines inhibited cell proliferation, blocked cell cycle in G1 phase, increased apoptosis rate and promoted the occurrence of ferroptosis. RNA-seq data suggested that CAPG silencing promotes cell cycle arrest, apoptosis, and ferroptosis by activating the P53 pathway. Therefore, CAPG has potential to serve as a prognostic marker as well as a cancer therapy target in the future.

2023-06-11 | GSE234395 | GEO

Galectin-9 suppresses tumor growth of colon cancer in vitro and in vivo [in vivo CW 90]

Project description:We examined the ability of Gal-9 to inhibit cell proliferation via apoptosis, and the effects of Gal-9 on cell cycle-related molecules in various human colon and colorectal cancer cell lines. In addition, Gal-9-mediated changes of activated tyrosine kinase receptors and angiogenic molecules were assessed using protein array chips in colon and colorectal cancer cells. Moreover, miRNA array analysis was performed to examine Gal-9-induced miRNA expression profiles. We also elucidated if Gal-9 inhibited tumor growth murine in vivo model.

2021-05-05 | GSE163789 | GEO

Galectin-9 suppresses tumor growth of colon cancer in vitro and in vivo [in vivo CW 30]

2021-05-05 | GSE163786 | GEO

Galectin-9 suppresses tumor growth of colon cancer in vitro and in vivo [in vivo Caco-2 90]

2021-05-05 | GSE163782 | GEO

Galectin-9 suppresses tumor growth of colon cancer in vitro and in vivo [in vivo Caco-2 30]

2021-05-05 | GSE163606 | GEO

Galectin-9 suppresses tumor growth of colon cancer in vitro and in vivo [in vitro Caco2]

2021-05-05 | GSE163599 | GEO